Cell Therapy Manufacturing Market CAGR To Exceed 8.25% by 2035, Due to the Growing Demand for Personalized Cell Therapies | Roots Analysis

According to our latest market report "Cell Therapy Manufacturing Market by Type of Cell Therapy, Source of Cells, Scale of Operation, Type of Manufacturer and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035", the global cell therapy manufacturing market size is projected to reach USD 14,017 million by 2035 from USD 6,343 million in 2025, growing at a CAGR of 8.25% in the forecast period 2025-2035.

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/cell-therapy-manufacturing/request-quote.html

Cell and gene therapy manufacturing is a complex process conducted in a highly controlled contamination-free environment and involves various critical steps such as the isolation, modification and expansion of immune cells, including T-cells and stem cells. Each step requires a specialized closed system and strict adherence to regulatory guidelines to ensure product safety and efficacy. Players are focusing their efforts on improving cell handling and processing equipment, enhancing ancillary materials and cell counting technologies, and addressing existing logistical concerns. As a result, it is gradually becoming important for cell therapy developers to invest in flexible and automated technologies, in order to cater to the challenges associated with human error in the manufacturing of these advanced therapy candidates. Such advancements are likely to assist companies in ensuring quality and consistency of products at affordable costs.

Cell Therapy Manufacturing Market Segments

Based on the type of cell therapy, the market is segmented into CAR-T Cell Therapies, Stem Cell Therapies, TCR Cell Therapies, TIL Cell Therapies, Dendritic Cell Therapies and Other Cell Therapies
1. The CAR-T cell therapies segment is likely to lead the market for cell therapies, capturing the largest revenue share of close to 64.1% in 2025.
2. The others segment including NK cells and cell modified gene therapies, is anticipated to show the highest growth potential during the forecast period at a CAGR of 16.15%

Based on the source of cells, the market is segmented into autologous cells, allogeneic cells and other cells
1. The autologous cells segment led the market for cell therapies, capturing the largest revenue share of more than 52.0% in 2025.
2. This segment is anticipated to growth at significant CAGR during the forecast period owing to the personalized nature of autologous therapies, which utilize patient's own cells, reducing the risk of immune rejection.

Based on the scale of operation, the market is segmented into clinical and commercial scale
1. The clinical scale segment led the market for cell therapies, capturing the largest revenue share of more than 70.0% in 2025.
2. The commercial scale segment is anticipated to grow at significant CAGR during the forecast period at a CAGR of 11.72%.

Based on the type of manufacturer, the market is segmented into contract manufacturing organizations and in-house manufacturers
1. The contract manufacturing organizations segment led the market for cell therapies, capturing the largest revenue share of close to 59.1% in 2025.
2. The in-house manufacturers segment is anticipated to show the highest growth potential during the forecast period at a CAGR of 9.68%.

Cell Therapy Manufacturing Market Regional Outlook
Based on the key geographical regions, the cell therapies market can be segmented into three major regions, including North America, Europe, Asia-Pacific and Rest of the World. Led by the US, North America is anticipated to capture the majority share of the cell therapy manufacturing market in 2025 and this trend is likely to remain unchanged during the forecast period. The Asia Pacific is accounted to be the fastest-growing segment of the market. The growth of the cell therapy manufacturing markets in the region is driven by rapid expanding of operations by establishing new facilities. This growth is largely driven by the reduced costs of clinical trials, availability of trained staff, and supportive regulatory frameworks in these regions.

To request a sample copy / brochure of this report, please visit:
https://www.rootsanalysis.com/reports/cell-therapy-manufacturing/request-sample.html

Key Report Takeaways
1. Currently, close to 200 industry players are engaged in cell therapy manufacturing of these, 45% of players are headquartered in North America
2. Immune cells and stem cells are the most prominent type of cells being manufactured by industry players; over 65% of the players operate at preclinical, clinical and commercial scales of operation
3. More than 80 non-industry players are currently engaged in the manufacturing of cell therapies, around 55% of theses players are based in the US
4. ~30% of the non-industry cell therapy manufacturers were established between 1951-2000; among these, nearly 80% of players utilize both autologous and allogeneic source of cells.
5. Close to 1,269 clinical trials have been registered till date to evaluate the various immune cell therapies; among which majority (65%) of these studies have been conducted across various trial sites in Asia-Pacific
6. The rising interest in this market is reflected from the diverse partnerships established among various stakeholders in the recent past; in fact, maximum ~25% of the deals have been inked in 2022
7. In order to meet the rising demand for cell therapies, players have made significant investments in expanding their existing capacities and capabilities, this trend was most pronounced in North America
8. Majority (~20%) of the big pharma activities in this domain have been led by Bristol Myers Squibb; of these, most of the initiatives were partnerships and collaborations with various stakeholders
9. ~95% of the current installed cell therapy manufacturing capacity (in terms of number of cleanrooms) is presently available with industry players; maximum capacity is installed in facilities based in North America
10. In order to reduce high capital investments and operational costs associated with setting up and maintaining an in-house production facility, the demand for pharmaceutical contract manufacturing is anticipated to rise significantly
11. Our proprietary total cost of ownership model provides an informed estimate of direct and indirect expenses while setting up a contract manufacturing facility in different regions, over a period of 20 years
12. The cell therapy manufacturing domain is poised to grow at an 8.25% CAGR; owing to high capital costs and advanced technologies, ~60% of manufacturing activities are expected to be outsourced to contract organizations
13. Driven by the increasing consumer awareness of, the rising prevalence of cancerous diseases and advancements in cell therapy manufacturing technologies, the market is poised for a steady growth in the future

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/cell-therapy-manufacturing/285.html#overview

Cell Therapy Manufacturing Market Key Players
Examples of key companies engaged in cell therapy manufacturing market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Advanced Therapies, AGC Biologics, Astellas Pharma, Catalent, Charles River Laboratories, City of Hope, Clinical Cell and Vaccine Production Facility (CVPF), Evotec, Fraunhofer Institute for Cell Therapy and Immunology and ImmunityBio.

Contact Details for Roots Analysis
Chief Executive: Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com
Website: https://www.rootsanalysis.com/

About Roots Analysis
Roots Analysis is a global leader in the market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.